Caredx opened higher at $80.62, compared with its previous close of $71.52. In the last trading session, the stock traded between $80.44 and $90.87. It showed an upward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Caredx is now worth
$ 168.06
giving a profit of
$ 68.06 (68.06%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
60%
Hold
40%
Sell
0%
Markets Today
Today's Change
+$14.19 (+19.84%)
Day High
$90.87
Day Low
$80.44
Day Open
$80.62
Prev Close
$71.52
Volume
22,39,345
1W Return
23.91%
1M Return
33.73%
3M Return
142.17%
6M Return
312.08%
1Y Return
500.22%
Fundamentals
Market Cap ($ Mn)
4,434
PE Ratio
23.94
PB Ratio
6.02
PEG Ratio
0.24
ROE
-6.28%
ROCE
-8.34%
EPS (TTM)
$2.15
Investment Returns
1 Week
23.91%
1 Month
33.73%
3 Months
142.17%
6 Months
312.08%
9 Months
312.08%
Financials
Quarterly
All values in $ Mn
84.7
Mar 25
86.7
Jun 25
100.1
Sep 25
108.4
Dec 25
117.7
Mar 26
131.9
Jun 26
Updates
16Oct
CareDx Q3FY26 Results: Earnings release set for October 29, 2026
CareDx will report Q3 2026 financial results on October 29, 2026. Conference call scheduled for 4:30 pm ET after market close. Webcast available via Investor Relations website.
14 days ago
1Aug
CareDx awards 15,822 RSUs to Executive Advisor James McNally
CareDx awarded 15,822 RSUs to Executive Advisor James McNally on July 30, 2026, under Nasdaq Rule 5635(c)(4). The awards vest in two equal tranches on January 2, 2027, and July 2, 2027, contingent on continued service.
3mo ago
31Jul
CareDx raises FY26 sales guidance to $490-500 million vs $455.9M estimate
CareDx reported Q2 2026 revenue of $132 million, up 52% YoY, and raised full-year 2026 guidance to $490-500 million, surpassing the $455.9 million estimate. GAAP net income turned positive at $111 million due to a $113 million gain from the Lab Products sale.
3mo ago
17Jul
CareDx stock surges 29% on Medicare coverage finalization
CareDx Inc. announced the finalization of the Medicare Local Coverage Determination (LCD) process for molecular testing related to solid organ allograft rejection, affirming coverage for kidney, heart, and lung transplant surveillance offerings. The final policy details specific testing limits for the first year and subsequent years, maintaining for-cause testing. Following the news, CareDx shares rose 28.89% to $38.34.
3mo ago
17Jul
BTIG raises CareDx price target to $45, maintains Buy
BTIG analyst Mark Massaro maintains a Buy rating on CareDx and raises the price target to $45 from $28, signaling a positive outlook for the NASDAQ-listed company.
3mo ago
16Jul
CareDx to report Q2 2026 financial results on July 30
CareDx announced it will release its Q2 2026 financial results on July 30, 2026, followed by a conference call at 4:30 p.m. ET. The company operates in precision medicine diagnostics for transplant, oncology, and cell therapy.
